newsroom.csl

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit - ...
newsroom.csl

World-class $1bn vaccine and antivenom manufacturing facility opens in Melbourne

Melbourne, Tuesday 2 December 2025 – Australia’s onshore vaccine manufacturing capabilities took a leap forward today as The Hon Mark Butler MP, Minister for Health, Disability and Ageing, opened CSL ...
newsroom.csl

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

KING OF PRUSSIA, Pa., Dec. 7, 2025 / PRNewswire / -- Global biopharma leader CSL (ASX:CSL; USOTC:CSLLY) today announced five-year (60-month) results from the pivotal Phase 3 HOPE-B study, confirming ...
newsroom.csl

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults

This historic approval of the world's first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine underscores CSL's promise to develop and deliver innovations when there is a public health need ...
newsroom.csl

Global Newsroom

- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic... CSL ...
newsroom.csl

Global Newsroom

Australia’s onshore vaccine manufacturing capabilities took a leap forward today as The Hon Mark Butler MP, Minister for Health, Disability and Ageing,... - 94% of patients (51 of 54) remained free ...